Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- GPCR Consortium, an International Partnership of Industry and Academia, Established: Ono
October 30, 2014
- Safety of Lorcaserin Confirmed in Concomitant Administration with Phentermine: Eisai
October 30, 2014
- Fujifilm to Buy US Vaccine CMO
October 29, 2014
- Mario Stein Named as New President of J&J Consumer Company
October 29, 2014
- Bristol’s Involvement in Sprycel Trial Could Contravene Ethics Code, but Not PAL: Probe
October 28, 2014
- US Judge Cuts Damages Takeda to Pay over Actos from US$6 Billion to US$27.65 Million
October 28, 2014
- GSK Files Lamictal Monotherapy for Typical Absence Seizures in Pediatric Patients
October 28, 2014
- NBI Files Spiriva-LABA Combination Drug for Approval
October 28, 2014
- 3 Major Wholesalers Acknowledge Illegal Diversion of Ethical Drugs to Wholesalers
October 28, 2014
- Xtandi Receives Positive CHMP Opinion for Treatment of Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer: Astellas
October 28, 2014
- Univ. of Tokyo, Pfizer Sign Strategic Partnership Deal for Drug Discovery Research
October 28, 2014
- Pfizer Japan Gearing Up for Reorganization in December, Pres. Umeda to Double as Head of New Unit
October 28, 2014
- PII Study Confirms Efficacy of Restless Legs Syndrome Treatment: Hisamitsu
October 28, 2014
- OTC Market Grew to 793 Billion Yen in 2013: Yano Research Institute
October 27, 2014
- Japan Arm of Hengrui Medicine Files Campto Generic for Approval
October 27, 2014
- Astellas Revises Package Insert for Xtandi Following Confirmation of Clinical Benefits in PIII Study
October 27, 2014
- Takeda Gains Worldwide Exclusive Rights for Amitiza Excluding Japan and China from Sucampo
October 24, 2014
- Toray Licenses Hemodialysis Pruritus Treatment to Orient EuroPharma in Taiwan
October 24, 2014
- Global Pharma Market to Reach US$1.3 Trillion by FY2018: IMS Official
October 23, 2014
- Taiho Receives Fast Track Designation from US FDA for Lonsurf
October 23, 2014
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…